Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
This study will evaluate the safety of infusion of the investigational cord blood units by
carefully documenting all infusion-related problems.
Phase
Phase 2
Funding Agency/Sponsor
Industrial
Disease
Pediatric Cancer
Enrollment Eligibility
Inclusion Criteria:
1. Diagnosis: Patients with disorders affecting the hematopoietic system that are
inherited, acquired, or result from myeloablative treatment.
2. Patients: Patients of any age and either gender
3. Cord blood product manufactured by the NCBP (at least one, if the graft contains more
than one units)
Exclusion Criteria:
1. Patients who are receiving licensed cord blood products (only)
2. Patients who are receiving unlicensed cord blood products from other banks (only)
3. Patients who are transplanted at non-US transplant centers
4. Patients who are receiving cord blood products that will be "manipulated" post-thaw
(e.g., ex vivo expansion, incubation in vitro, etc.)